$ITNS The company is also focused on developing a Cannabinoid-Based Product presently named "Cloud9" to meet a growing need for the treatment and management of acute and chronic pain conditions. The CBD-based product will be a unique sublingual that dissolves under the tongue as a convenient delivery method and the Company plans on making Cloud9 available in a unit range of 100 - 200 mg.